Wednesday, August 29, 2018 4:19:21 PM
"Based on progress made to-date, the Company currently expects the completion of the Functional Unit phase in calendar 4Q 2018 and the Verified Unit phase in calendar 1Q 2019. The Company believes that the miniaturization, imaging quality and cost reduction goals for the i/Blue Imaging System will be achieved as Optel optimizes the system and works toward commercialization."
"Necessary documents to begin the FDA process, including clinical study recommendation, are being prepared for submission. The timing of the clinical studies is tied to the final verification of the i/Blue Imaging System and is currently anticipated to begin late calendar 1Q 2019 or during calendar 2Q 2019. Depending on the FDA device classification and schedule, the Company is planning for potential commercialization in calendar year 2020."
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM